Chemotherapy induces multiple sclerosis-like neuropathologies that can be rescued by clobetasol.

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Cell Death and Differentiation

• Publication date

  2025-12-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41418-025-01635-zPMID 41388189
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2024cited by this paper
• The neuropathobiology of multiple sclerosis

  2024cited by this paper
• Gamma entrainment using audiovisual stimuli alleviates chemobrain pathology and cognitive impairment induced by chemotherapy in mice

  2024cited by this paper
• Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas

  2023cited by this paper
• Neuropsychological functioning during chemotherapy with temozolomide in high-grade glioma patients: a retrospective single centre study

  2023cited by this paper
• Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas

  2022cited by this paper
• World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.

  2022cited by this paper
• Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing

  2021cited by this paper
• Life-long oligodendrocyte development and plasticity

  2021cited by this paper
• Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases

  2020cited by this paper
• AMPK and TOR: The Yin and Yang of Cellular Nutrient Sensing and Growth Control.

  2020cited by this paper
• Molecular Control of Oligodendrocyte Development.

  2019cited by this paper
• Loss of Adaptive Myelination Contributes to Methotrexate Chemotherapy-Related Cognitive Impairment.

  2019cited by this paper
• Methotrexate Chemotherapy Induces Persistent Tri-glial Dysregulation that Underlies Chemotherapy-Related Cognitive Impairment.

  2019cited by this paper
• Multiple Sclerosis

  2018cited by this paper
• Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide: A Single-center Prospective Study

  2018cited by this paper
• A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy

  2018cited by this paper
• AMPK Negatively Regulates Peripheral Myelination via Activation of c-Jun

  2017cited by this paper
• Antibody-drug conjugates—an emerging class of cancer treatment

  2016cited by this paper
• Neurodegenerative diseases: Repurposing for remyelination

  2015cited by this paper
• Glioma

  2015cited by this paper
• Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo

  2015cited by this paper
• Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system.

  2015cited by this paper
• Neural correlates of chemotherapy-related cognitive impairment.

  2014cited by this paper
• Oligodendrocyte Precursor Cell-Intrinsic Effect of Rheb1 Controls Differentiation and Mediates mTORC1-Dependent Myelination in Brain

  2014cited by this paper
• Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea

  2014cited by this paper
• Identification of Tmem10 as a Novel Late-stage Oligodendrocytes Marker for Detecting Hypomyelination

  2013cited by this paper
• Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.

  2013cited by this paper
• Chemobrain: a systematic review of structural and functional neuroimaging studies.

  2013cited by this paper
• Temozolomide-Related Hematologic Toxicity

  2013cited by this paper
• Rheb1 is required for mTORC1 and myelination in postnatal brain development.

  2011cited by this paper
• Chemotherapy‐induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients

  2011cited by this paper
• Activation of AMP-activated Protein Kinase by Temozolomide Contributes to Apoptosis in Glioblastoma Cells via p53 Activation and mTORC1 Inhibition*

  2010cited by this paper
• Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models

  2010cited by this paper
• The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis

  2009cited by this paper
• Mechanisms of Disease: temozolomide and glioblastoma—look to the future

  2008cited by this paper
• A history of cancer chemotherapy.

  2008cited by this paper
• Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy.

  2006cited by this paper
• Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects.

  2006cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• ‘Chemobrain’ in breast carcinoma?

  2004cited by this paper
• Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer.

  2003cited by this paper
• Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.

  2002cited by this paper
• Cognitive function in breast cancer patients receiving adjuvant chemotherapy.

  2000cited by this paper
• Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma

  1999cited by this paper
• Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.

  1998cited by this paper
• Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer

  1995cited by this paper

• No citing papers are available for this paper.